INTRODUCTION
============

Thyroid malignancies are predicted to become the fifth leading cause of cancer in women worldwide \[[@B1]\]. They are categorized along a continuum, with well differentiated thyroid carcinoma (WDTC) on one end and anaplastic thyroid carcinoma (ATC) on the other. Poorly differentiated thyroid carcinoma (PDTC) exhibits a unique histologic architecture and represents the bridge between WDTC and ATC \[[@B2]\]. It was previously classified as a WDTC variant until being recognized in 2004 by the World Health Organization Classification of Endocrine Tumors as a distinct entity, defined as a "follicular cell neoplasm with limited evidence of structural follicular cell differentiation that occupies morphologically and behaviorally an intermediate position between differentiated and undifferentiated carcinoma" \[[@B3]\]. This definition was further refined in the 2006 Turin criteria, which stated that a thyroid malignancy must demonstrate a trabecular, insular, or solid (TIS) growth pattern; the absence of the conventional nuclear patterns of papillary carcinoma; and the presence of at least one of the following features: convoluted nuclei, mitotic activity, or necrosis \[[@B4]\].

Similarly to other thyroid cancer subtypes, PDTC occurs more commonly in women, most often in the sixth decade of life \[[@B5][@B6]\]. It is generally rare, with an incidence rate of 0.23% to 2.6% among patients with thyroid carcinomas \[[@B7][@B8]\]. Regional variations exist, with frequencies of up to 15% in Northern Italy, suggesting that risk factors such as iodine deficiency and radiation exposure play a role in disease development \[[@B9]\]. Consistent with their intermediate differentiation, PDTCs can display both local and distant aggressiveness. The poor prognostic factors identified in the literature include age \>45 years, a mitotic index of \>3/high power field (HPF), necrosis, a tumor size \>4 cm, higher stage, positive surgical margins, local recurrence, and distant metastasis \[[@B8][@B10][@B11]\].

Because of its rarity and intermittent biologic aggressiveness, knowledge regarding the optimal management of PDTC remains limited. Furthermore, the majority of published data are from Western countries; data from Southeast Asia are lacking. Given the ethnic and geographic differences in tumor behavior, this study aimed to fill this knowledge gap by documenting the 10-year experience of a tertiary medical center in the Philippines with regard to PDTC.

METHODS
=======

The study protocol was approved by the Institutional Technical and Ethics Review Board prior to its commencement.

Study participants and procedures
---------------------------------

All patients \>18 years old diagnosed with a thyroid malignancy from 2006 to 2015 at the Philippine General Hospital (PGH) were identified using logbooks from the Department of Pathology. For purposes of standardization, only cases with histopathology performed at the PGH Department of Pathology were included. The slides were reviewed by a pathologist to determine whether a diagnosis of PDTC was made according to the Turin criteria. For confirmed PDTC cases, patient records were retrieved and a data collection form was used to collect information regarding demographics, clinical and histopathological characteristics, the treatment given, and the clinical course and outcome. Those with incomplete data and/or who were lost to follow-up were included and reported accordingly. Patient data were tabulated and compared with data from foreign studies on PDTC, as well as with data on WDTC and ATC patients in the Philippines. In our institution, there is no single standard protocol for the treatment of PDTC.

Data management and analysis
----------------------------

Statistical analysis was performed using Stata SE version 13 software (StataCorp, College Station, TX, USA). Descriptive statistics included the mean±standard deviation for normally distributed quantitative variables, the median and interquartile range for non-normally distributed quantitative variables, and the frequency and percentage for qualitative variables. Tests of association (the *t* test for independent means and the *Z* test for two proportions) were employed to compare these characteristics with PDTC patients from other countries, as well as with WDTC and ATC patients in the Philippines. Statistical significance was set at *P*\<0.05.

RESULTS
=======

Out of the 761 thyroid malignancies identified over the 10-year period, a total of 18 cases satisfied the Turin criteria for the diagnosis of PDTC. The median age was 62 years (range, 40 to 75), with females comprising the majority (72%). There was no documented history of radiation exposure in any patient. All patients had goiter on presentation, with a mean size of 8.6 cm and a median duration of 9 years. More than half (61%) were TNM (tumor, node, metastasis) stage IV on diagnosis, with a mean maximum tumor dimension of 5.8 cm and a mean mitotic index of 10.1/HPF. Necrosis was present in the majority (72%). In terms of PDTC subtype, insular and trabecular patterns were equally common. Extrathyroidal extension was documented in eight patients, while five patients each had nodal and distant metastasis. With regard to treatment, all but one patient underwent surgery, and more than half underwent at least a total thyroidectomy with neck dissection as necessary. In contrast, less than half underwent adjuvant radioactive iodine (RAI) ablation, and no patients received external beam radiotherapy (EBRT) or chemotherapy. Prior to being diagnosed with PDTC, four patients were diagnosed with WDTC and one patient had Hashimoto thyroiditis. The 5-year survival rate was 83%. Three patients (16.7%) died at a median of 12 months after diagnosis. For cases of recurrence, the median time from diagnosis to recurrence was 39 months. [Table 1](#T1){ref-type="table"} summarizes the patient characteristics, which are individually shown in [Table 2](#T2){ref-type="table"}. [Fig. 1](#F1){ref-type="fig"}, on the other hand, shows the survival curves of the study patients after PDTC diagnosis.

DISCUSSION
==========

This is the first study to document the characteristics of PDTC patients in a Southeast Asian population. We compared our data with those of PDTC patients from other regions ([Table 3](#T3){ref-type="table"}) and found similarities in terms of age and female predominance. The median age and mean tumor size of our sample, however, were the highest across all studies. These, coupled with the long duration of goiter, can be explained by a general delay in diagnosis due to limitations in medical access experienced by many patients treated at our institution.

The rates of extrathyroidal extension, lymph node metastasis, and distant metastasis in our study are also consistent with the findings of other studies. In general, extrathyroidal extension has been observed in 30% to 59% of PDTC patients, while distant metastasis has been found to occur in 13% to 33% of cases. The exceptions are the case series of Cherkaoui et al. \[[@B8]\] in Morocco, which did not find any patient with extrathyroidal extension or distant metastasis (as all cases were TNM stage III or lower); the study of Volante et al. \[[@B6]\] in Italy, which did not report nodal or distant metastasis, but reported 54% of cases to exhibit wide vascular invasion (\>3 blood vessels outside the tumor capsule); and the study of Lin et al. \[[@B12]\] in Taiwan, which did not report extrathyroidal extension or nodal metastasis, but documented eight patients with local invasion. These findings are consistent with the inherent biologic aggressiveness of this disease.

It is important to note that aside from our study, only one other PDTC study utilized the Turin criteria in case selection \[[@B8]\]. The rest utilized a combination of criteria including TIS growth patterns coupled with vascular invasion or follicular differentiation with tumor necrosis \[[@B5][@B6][@B7][@B11][@B12]\]. Such differences in selection criteria may have influenced the survival rate. For instance, while most studies reported 5-year survival rates of \>80%, the studies of Jung et al. \[[@B11]\] in Korea, Lin et al. \[[@B12]\] in Taiwan, and Ibrahimpasic et al. \[[@B7]\] in the USA reported figures of only \>60%. A common feature of the Korean and American studies is the presence of necrosis---a known poor prognostic factor---as a prerequisite for case inclusion \[[@B7][@B11]\]. In contrast, the Taiwan study had the highest rate of distant metastasis, which may have accounted for the lower survival rate \[[@B12]\]. For studies that utilized the Turin or TIS criteria for diagnosis, there appeared to be no predominant subtype; our study found insular and trabecular patterns to be equally common, while other studies had discrepant findings.

Given the lack of previous standard diagnostic criteria, there are no universal guidelines on the management of PDTC patients. The initial treatment commonly consists of total thyroidectomy with neck dissection whenever necessary \[[@B13]\]. The role of adjuvant therapies such as RAI, EBRT, and chemotherapy are less clear, as no study has shown these treatments to have definite benefits \[[@B7]\]. Thus, they are often reserved for patients with a high locoregional recurrence risk, those with gross residual or inoperable disease, and those needing palliative therapy \[[@B14]\]. Our study had the lowest RAI rate across all studies. This may reflect the financial constraints of many patients in our institution, as well as the reluctance of healthcare providers to pursue a treatment modality less established for this indication. Despite the low RAI rate, however, our study still found a 5-year survival rate of 83%. New therapies in the form of mo-lecular inhibitors targeting the *TP53* gene, the MAP (mitogen-activated protein) kinase pathway, and/or the PI3K (phosphoinositide 3-kinase)/AKT pathway may offer additional options to high-risk PDTC patients \[[@B15]\].

We also compared our study results to data on Filipino WDTC patients ([Table 4](#T4){ref-type="table"}). While the same female predominance was found as was observed among Filipino PDTC patients, the WDTC patients were significantly younger, had smaller tumor sizes on presentation, and had higher rates of stage I disease and lower rates of stage IV disease and distant metastasis. In contrast, the rates of nodal metastasis did not appear to differ between these two groups. This can be explained by the fact that the majority of WDTC cases involved papillary thyroid carcinoma, which exhibits a tendency for nodal metastasis \[[@B16]\]. In terms of treatment, significantly more WDTC patients received curative surgery (at least a total thyroidectomy), while significantly more PDTC patients received only palliative surgery (tumor debulking with or without tracheostomy), as the greater tumor burden of the latter group often precluded complete surgical resection. This may have contributed to the presence of a significantly lower 5-year survival rate and higher 5-year persistence and/or recurrence rates in PDTC patients than in WDTC patients, consistent with the literature \[[@B17][@B18][@B19]\]. Finally, the fact that three PDTC cases had prior WDTC supports the theory that thyroid cancer can behave as a continuum with regard to the progression of genetic alterations \[[@B13]\].

We also compared our study results to data on Filipino ATC patients ([Table 5](#T5){ref-type="table"}). Filipino ATC patients were observed to have significantly larger tumors and higher rates of nodal metastasis and obstructive symptoms. The 5-year survival rate was also significantly lower for Filipino ATC patients, with a significantly shorter duration from diagnosis to death \[[@B20]\]. In all, our study results are generally consistent with the finding that the behavior of PDTC is intermediate between WDTC and ATC.

Our study faced several limitations. A history of prior neck irradiation was not elicited in any patient since neck irradiation as a form of therapy has not been widely used in the Philippines in the past \[[@B16]\]. Iodine status was also not evaluated in any patient, although iodine deficiency has been posited as a risk factor for PDTC development. Genetic and molecular data were also not available. These limitations stemmed from the retrospective design of the study. We also had a very small sample size due to the rarity of the disease and the limited availability of slides (only from the past 10 years) in the Department of Pathology. This precluded the performance of multivariate regression analysis to determine possible prognostic factors in our patients.

In conclusion, the behavior of PDTC in this Southeast Asian population was similar to patterns observed in other regions, with intermediate features between WDTC and ATC. With appropriate surgery, excellent 5-year survival rates can be achieved. The role of adjuvant therapy, however, remains unclear. We recommend larger studies to determine factors predictive of poorer outcomes and mortality in these patients.
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###### Summary Characteristics of Poorly Differentiated Thyroid Carcinoma Cases (*n*=18)
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  Characteristic                                                  Value
  --------------------------------------------------------------- -------------
  Age, yr                                                         62 (40--75)
  Sex                                                             
   Female                                                         13 (72.2)
   Male                                                           5 (27.8)
  History of radiation exposure                                   0
  Clinical presentation                                           
   Goiter                                                         18 (100.0)
    Size on presentation, cm                                      8.6±3.9
    Median duration, yr                                           9
   Dysphagia                                                      7 (38.9)
   Difficulty of breathing                                        7 (38.9)
   Hoarseness                                                     5 (27.8)
   Weight loss                                                    4 (22.2)
   Neck pain                                                      2 (11.1)
   Dry cough                                                      2 (11.1)
   Easily fatigued                                                2 (11.1)
   Generalized weakness                                           1 (5.6)
   Globus sensation                                               1 (5.6)
  TNM stage upon diagnosis                                        
   Stage I                                                        1 (5.6)
   Stage II                                                       1 (5.6)
   Stage III                                                      5 (27.8)
   Stage IV                                                       
    IVa                                                           6 (33.3)
    IVb                                                           1 (5.6)
    IVc                                                           4 (22.2)
  pT stage                                                        
   pT1--2                                                         5 (27.8)
   pT3                                                            7 (38.9)
   pT4a                                                           5 (27.8)
   pT4b                                                           1 (5.6)
  Greatest tumor dimension, cm                                    5.8±2.7
  Predominant (≥50%) histologic pattern                           
   Insular                                                        8 (44.4)
   Trabecular                                                     7 (38.9)
   Solid                                                          3 (16.7)
  Mitotic index, /HPF                                             10.1±9.3
  Presence of necrosis                                            13 (72.2)
  Surgical margin status                                          
   Positive                                                       7 (38.9)
   Negative                                                       11 (61.1)
  Extrathyroidal extension                                        8 (44.4)
  pN stage                                                        
   pN0                                                            13 (72.2)
   pN1a                                                           2 (11.1)
   pN1b                                                           3 (16.7)
  Distant metastasis                                              
   Lung                                                           3 (16.7)
   Bone                                                           2 (11.1)
  Treatment                                                       
   Surgery                                                        
    Total thyroidectomy with neck dissection                      5 (27.8)
    Total thyroidectomy only                                      5 (27.8)
    Subtotal thyroidectomy followed by completion thyroidectomy   2 (11.1)
    Lobectomy followed by completion thyroidectomy                1 (5.6)
    Tumor debulking with tracheostomy                             3 (16.7)
    Tumor debulking only                                          1 (5.6)
    None                                                          1 (5.6)
   RAI                                                            8 (44.4)
    Cumulative dose, mCi                                          181.3
   EBRT                                                           0
   Chemotherapy                                                   0
  Previous pathologies                                            
   Papillary carcinoma                                            3 (16.7)
   Follicular carcinoma                                           1 (5.6)
   Hashimoto thyroiditis                                          1 (5.6)
  Comorbidities                                                   
   Hypertension                                                   8 (44.4)
   Diabetes                                                       4 (22.2)
   Pulmonary disease                                              2 (11.1)
  Clinical outcome                                                
   Alive, with disease cure                                       6 (33.3)
   Alive, with disease persistence and/or recurrence              9 (50.0)
    Median duration from diagnosis to recurrence, mo              39
   Dead                                                           3 (16.7)
    Median duration from diagnosis to death, mo                   12
  Overall 5-year survival rate, %                                 83.3

Values are expressed as median (range), number (%), or mean±SD.

TNM, tumor, node, metastasis; HPF, high power field; RAI, radioactive iodine; EBRT, external beam radiotherapy.

###### Individual Characteristics of Poorly Differentiated Thyroid Carcinoma Cases (*n*=18)
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  Patient   Initial expression                                                            TNM stage   Extent of surgery                   Surgical margin   Adjuvant therapy   Recurrence/Persistence   Recurrence-free duration   Recurrence site   Final status
  --------- ----------------------------------------------------------------------------- ----------- ----------------------------------- ----------------- ------------------ ------------------------ -------------------------- ----------------- --------------
  1         Goiter                                                                        I           TT with ND                          Negative          RAI                No                       \-                         \-                ADC
  2         Goiter, dysphagia                                                             II          TT only                             Negative          RAI                No                       \-                         \-                ADC
  3         Goiter                                                                        III         TT with ND                          Negative          RAI                No                       \-                         \-                ADC
  4         Goiter                                                                        III         TT only                             Positive          RAI                No                       \-                         \-                ADC
  5         Goiter                                                                        III         TT only                             Negative          RAI                No                       \-                         \-                ADC
  6         Goiter, dysphagia                                                             III         TT only                             Negative          RAI                No                       \-                         \-                ADC
  7         Goiter, easily fatigued                                                       IVb         Lobectomy followed by CT            Negative          \-                 Recurrence               24 months                  Neck              ADR
  8         Goiter                                                                        IVc         STT followed by CT                  Positive          \-                 Recurrence               36 months                  Neck              ADR
  9         Goiter                                                                        III         STT followed by CT                  Negative          \-                 Persistence              \-                         \-                ADP
  10        Goiter, difficulty breathing, neck pain, dry cough                            IVa         Tumor debulking with tracheostomy   Negative          \-                 Persistence              \-                         \-                ADP
  11        Goiter, globus sensation                                                      IVa         TT with ND                          Negative          \-                 Persistence              \-                         \-                ADP
  12        Goiter, hoarseness, dysphagia, difficulty breathing, weight loss              IVa         Tumor debulking with tracheostomy   Positive          \-                 Persistence              \-                         \-                ADP
  13        Goiter, difficulty breathing, dry cough                                       IVa         TT with ND                          Positive          \-                 Persistence              \-                         \-                ADP
  14        Goiter, hoarseness, dysphagia                                                 IVc         TT only                             Negative          RAI                Persistence              \-                         \-                ADP
  15        Goiter, difficulty breathing, easily fatigued, weight loss                    IVc         TT with ND                          Negative          RAI                Persistence              \-                         \-                ADP
  16        Goiter, hoarseness, dysphagia, difficulty breathing, weakness                 IVa         No surgery done                     Positive          \-                 Persistence              \-                         \-                Dead
  17        Goiter, hoarseness, dysphagia, difficulty breathing, neck pain, weight loss   IVa         Tumor debulking only                Positive          \-                 Persistence              \-                         \-                Dead
  18        Goiter, hoarseness, dysphagia, difficulty breathing, weight loss              IVc         Tumor debulking with tracheostomy   Positive          \-                 Persistence              \-                         \-                Dead

TNM, tumor, node, metastasis; TT, total thyroidectomy; ND, neck dissection; RAI, radioactive iodine; ADC, alive with disease cure; CT, completion thyroidectomy; ADR, alive with disease recurrence; STT, subtotal thyroidectomy; ADP, alive with disease persistence.

###### Comparison of Features of PDTC Patients among Different Studies
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  Characteristic                     Philippines              USA \[[@B7]\]                                                          Italy \[[@B6]\]   Japan \[[@B5]\]        Korea \[[@B11]\]       Taiwan \[[@B12]\]   Morocco \[[@B8]\]
  ---------------------------------- ------------------------ ---------------------------------------------------------------------- ----------------- ---------------------- ---------------------- ------------------- -------------------
  Sample size                        18                       91                                                                     183               29                     49                     67                  7
  Age at diagnosis, yr               62.0                     59.0                                                                   56.3              57.0                   49.3                   50.3                60.0
  Female sex, %                      72.2                     62.0                                                                   69.4              75.9                   73.5                   64.2                85.7
  Criteria used for PDTC diagnosis   Turin criteria           Follicular cell differentiation+necrosis or mitotic index \>5/10 HPF   TIS pattern       TIS pattern            TIS pattern+necrosis   TIS pattern         Turin criteria
  Predominant histology              Insular and trabecular   NR                                                                     Insular           Solid and trabecular   Solid and trabecular   NR                  Insular
  Mean tumor size, cm                5.8                      \<4                                                                    5.3               3.1                    4.7                    4.2                 4.0
  Extrathyroidal extension, %        44.4                     30.0                                                                   54.0              55.2                   59.0                   NR                  0
  Lymph node metastasis, %           27.8                     40.7                                                                   NR                72.4                   29.0                   NR                  57.1
  Distant metastasis, %              27.8                     26.0                                                                   NR                13.8                   33.0                   49.3                0
  Adjuvant RAI, %                    44.4                     73.6                                                                   45.4              NR                     78.0                   67.2                100.0
  5-Year survival rate, %            83.3                     62.0                                                                   85.0              89.3                   69.4                   62.7                85.0

PDTC, poorly defined thyroid carcinoma; HPF, high power field; TIS, trabecular, insular, or solid; NR, not reported; RAI, radioactive iodine.

###### Features of Filipino PDTC Patients as Compared to WDTC Patients
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  Characteristic                                 WDTC \[[@B15]\]   PDTC          *P* value
  ---------------------------------------------- ----------------- ------------- -----------
  Sample size                                    0728              18            \-
  Age at diagnosis, yr                           44 (18--82)       61 (40--75)   \<0.001
  Female sex, %                                  85.9              72.2          0.051
  Greatest tumor dimension, cm                   2.9               5.8           \<0.001
  TNM stage on diagnosis, %                                                      
   Stage I                                       58.4              5.6           \<0.001
   Stage II                                      13.2              5.6           0.172
   Stage III                                     13.1              27.8          0.035
   Stage IV                                      15.4              61.1          \<0.001
  Lymph node metastasis, %                       18                27.8          0.144
  Distant metastasis, %                          4.9               27.8          \<0.001
  Treatment, %                                                                   
   Initial surgery                               100               94.4          
    Total thyroidectomy with neck dissection     23.9              27.8          0.351
    Total thyroidectomy only                     55.6              27.8          0.010
    Near total thyroidectomy                     3.0               0             0.228
    Subtotal thyroidectomy                       9.5               11.1          0.410
    Lobectomy                                    8.0               5.6           0.355
    Tumor debulking with tracheostomy            0                 16.7          \<0.001
    Tumor debulking only                         0                 5.6           \<0.001
   RAI                                           71.8              44.4          0.339
   EBRT                                          2.1               0             0.267
   Chemotherapy                                  0.3               0             0.408
  5-Year survival rate, %                        99.5              83.3          \<0.001
  5-Year persistence and/or recurrence rate, %   18.8              50.0          0.001

Values are expressed as median (range). PDTC, poorly differentiated thyroid carcinoma; WDTC, well differentiated thyroid carcinoma; TNM, tumor, node, metastasis; RAI, radioactive iodine; EBRT, external beam radiotherapy.

###### Features of Filipino PDTC Patients as Compared to ATC Patients
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  Characteristic                         PDTC          ATC \[[@B19]\]   *P* value
  -------------------------------------- ------------- ---------------- -----------
  Sample size                            18            15               \-
  Age, yr                                62 (40--75)   63 (36--73)      0.370
  Female sex, %                          72.2          53.0             0.127
  Greatest tumor dimension, cm           5.8           10.0             \<0.001
  Clinical presentation, %                                              
   Goiter                                100.0         60.0             0.002
   Hoarseness                            27.8          60.0             0.031
   Dysphagia                             38.9          80.0             0.009
   Difficulty of breathing               38.9          60.0             0.114
   Neck pain                             11.1          40.0             0.027
   Weight loss                           22.2          60.0             0.014
   Cough                                 11.1          33.0             0.062
  Lymph node metastasis, %               27.8          73.0             0.005
  Distant metastasis, %                  27.8          47.0             0.127
  Treatment, %                                                          
   Surgery                               94.4          47.0             0.001
    Curative                             72.2          20.0             0.001
    Palliative                           22.2          26.7             0.382
   RAI                                   44.4          0                \<0.001
   EBRT                                  0             20.0             0.023
   Chemotherapy                          0             0                \-
  5-Year survival rate, %                83.3          0                \<0.001
  Duration from diagnosis to death, mo   12            3                \<0.001

Values are expressed as median (range).

PDTC, poorly differentiated thyroid carcinoma; ATC, anaplastic thyroid carcinoma; RAI, radioactive iodine; EBRT, external beam radiotherapy.
